EU issues pay-for-delay fines after nine-year probe

The European Commission has fined Cephalon and Teva a total of €60.5 million for entering into pay-for-delay agreements for a sleep disorder drug, although the enforcer said it no longer believes these types of agreements are a “big issue” in terms of their prevalence.


Get unlimited access to all Global Competition Review content